The company has executed two landmark collaborations worth up to $2.2 billion combined. In April 2026, the global strategic collaboration with Astellas to advance the PSMA-targeted dual-masked T-cell engager VIR-5500 closed with the first patient dosed in Phase 1 dose-expansion cohorts. Strategic partnerships and financing have extended cash runway to 2028.
Cyborg Score Rationale
Vir reported Q1 2026 net loss of $125.7 million, representing a 4% increase year-over-year. However, the company shows strong clinical momentum with positive Phase 1 data for VIR-5500 showing dose-dependent anti-tumor activity presented at the 2026 ASCO Genitourinary Cancers Symposium. As of March 31, 2026, the company had $809.3 million in cash, cash equivalents and investments.
Top Insights
Global collaboration with Astellas worth up to $315 million upfront plus equity investment for VIR-5500 closed in April 2026 with first patient dosed in Phase 1 expansion cohorts
Phase 2 SOLSTICE data for chronic hepatitis delta combination therapy showed 77% achieved undetectable hepatitis delta virus RNA at Week 72, increasing to 88% at Week 96
Pivotal Phase 3 trials anticipated to initiate in 2027 for VIR-5500 prostate cancer program
ECLIPSE 1 topline data expected in Q4 2026 for CHD combination therapy; VIR-5818 Phase 1 dose escalation response data expected in second half of 2026
Named Competitors
Rigel Pharmaceuticals — Clinical-stage biopharmaceutical company
Allogene Therapeutics — Cell therapy development
Adaptimmune Therapeutics — T-cell immunotherapy
Sorrento Therapeutics — Immunotherapy platform
Synlogic — Synthetic biology therapeutics
Recent Developments
(May 2026) Closed global strategic collaboration with Astellas for VIR-5500 prostate cancer program with $315 million upfront payment
(May 2026) Presented positive Phase 1 VIR-5500 data at ASCO Genitourinary Cancers Symposium showing dose-dependent anti-tumor activity
(Q1 2026) Completed public offering with gross proceeds of $172.5 million
(May 2026) Scheduled to present Week 96 Phase 2 SOLSTICE data for chronic hepatitis delta at EASL Congress
Open the full interactive Vir Biotechnology, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.